Medpace终止旧回购授权并批准新10亿美元回购计划

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________________________________________________

FORM 8-K

______________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2026

______________________________________________________

Medpace Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

______________________________________________________

Registrant’s Telephone Number, Including Area Code: 513 579-9911

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

______________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On October 21, 2026, Medpace Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026. The full text of the press release was posted on the Company’s internet website and is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, Item 2.02, including the press release attached as Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

Item 8.01 Other Events.

Effective October 20, 2026 (“Effective Date”), the Company’s Board of Directors (“Board”) terminated the Company’s current stock repurchase authorization of the Company’s common stock, $0.01 par value (“common stock”) which was set to expire on December 31, 2026. As of the Effective Date, this repurchase authorization had $527.0 million remaining.

Effective as of the Effective Date, the Board approved a new stock repurchase authorization, pursuant to which the Company is authorized to repurchase up to $1.0 billion shares of common stock until December 31, 2028, at the discretion of the Company’s management. Repurchases under this new authorization may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to alternative uses of capital, prevailing market conditions, applicable regulatory requirements, and other considerations. Under the new authorization, any such repurchases may be executed using open market purchases, privately negotiated transactions, transactions in accordance with Rule 10b5-1 of the Exchange Act, or other transactions, and will be funded from cash on hand. The new authorization does not obligate the Company to acquire any minimum amount of common stock and the new authorization may be modified, limited, extended, suspended or terminated by the Board at any time without prior notice.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.